# WIA-BIO-006 — Phase 3: Protocol > Tissue-engineering canonical Phase 3: protocols (bioprinting + bioreactor + vascularization + cross-linking + cell-seeding). # WIA-BIO-006: Tissue Engineering Specification v1.0 > **Standard ID:** WIA-BIO-006 > **Version:** 1.0.0 > **Published:** 2025-12-26 > **Status:** Active > **Authors:** WIA Biomedical Engineering Research Group --- ## Table of Contents 1. [Introduction](#1-introduction) 2. [Scaffold Materials and Design](#2-scaffold-materials-and-design) 3. [3D Bioprinting Protocols](#3-3d-bioprinting-protocols) 4. [Bioreactor Systems](#4-bioreactor-systems) 5. [Vascularization Strategies](#5-vascularization-strategies) 6. [Cell Culture and Seeding](#6-cell-culture-and-seeding) 7. [Quality Testing Standards](#7-quality-testing-standards) 8. [Regulatory Requirements](#8-regulatory-requirements) 9. [Implementation Guidelines](#9-implementation-guidelines) 10. [References](#10-references) --- ## 3. 3D Bioprinting Protocols ### 3.1 Bioprinting Technologies #### 3.1.1 Extrusion-Based Bioprinting **Principle**: Pneumatic or mechanical extrusion of bioink **Parameters**: ``` Pressure: 10-200 kPa Nozzle diameter: 100-1000 μm Print speed: 5-50 mm/s Layer height: 50-500 μm Temperature: 4-37°C ``` **Advantages**: - High cell density (10⁶-10⁸ cells/mL) - Multiple materials - Cost-effective **Limitations**: - Lower resolution - Shear stress on cells #### 3.1.2 Inkjet Bioprinting **Principle**: Droplet-based deposition (thermal or piezoelectric) **Parameters**: ``` Droplet volume: 1-300 pL Frequency: 1-10 kHz Resolution: 20-100 μm Viscosity: 3-12 mPa·s Cell viability: >85% ``` **Advantages**: - High resolution - High speed - Low cost #### 3.1.3 Laser-Assisted Bioprinting **Principle**: Laser-induced forward transfer (LIFT) **Parameters**: ``` Laser wavelength: 532-1064 nm Pulse duration: 10-100 ns Energy: 1-100 μJ/pulse Resolution: <10 μm Cell viability: >95% ``` **Advantages**: - Highest resolution - Minimal cell damage - No nozzle clogging **Limitations**: - High cost - Complex setup - Low throughput ### 3.2 Bioink Formulation #### 3.2.1 Cell-Laden Hydrogels **Components**: 1. **Polymer base**: Gelatin, alginate, collagen, hyaluronic acid 2. **Cross-linker**: Ca²⁺, light (405 nm), temperature 3. **Cells**: 10⁶-10⁸ cells/mL 4. **Growth factors**: Optional (VEGF, BMP, FGF) **Rheological requirements**: ``` Viscosity (η): 30-6000 mPa·s Shear-thinning: Yes Storage modulus (G'): 100-10,000 Pa Loss modulus (G"): 10-1,000 Pa G' > G" (gel-like behavior) ``` #### 3.2.2 Decellularized ECM Bioinks **Preparation**: 1. Decellularize tissue (SDS, Triton X-100) 2. Solubilize ECM (pepsin, pH 2-3) 3. Neutralize to pH 7.4 4. Add cells (10⁶-10⁷ cells/mL) **Properties**: - Tissue-specific biochemical cues - Natural architecture - Enhanced cell function ### 3.3 Bioprinting Protocol #### 3.3.1 Pre-Print Preparation 1. **Design CAD model** (STL file) 2. **Slice into layers** (10-200 μm) 3. **Generate G-code** (toolpath) 4. **Prepare bioink** (mix cells + hydrogel) 5. **Calibrate printer** (pressure, temperature) 6. **Load cartridges** (maintain sterility) #### 3.3.2 Printing Process ``` 1. Initialize system (UV sterilize) 2. Set parameters: - Pressure: 20-100 kPa - Speed: 10-30 mm/s - Temperature: 15-25°C 3. Prime nozzle (remove air bubbles) 4. Print first layer (adhesion critical) 5. Continue layer-by-layer 6. Monitor visually (camera) 7. Cross-link if needed (UV, Ca²⁺) ``` #### 3.3.3 Post-Print Processing 1. **Cross-linking**: UV (5-15 min), ionic, thermal 2. **Culture medium addition**: Supplement with nutrients 3. **Incubation**: 37°C, 5% CO₂ 4. **Maturation**: 1-4 weeks in bioreactor ### 3.4 Quality Control for Bioprinting **Print fidelity**: ``` F = (1 - |D_actual - D_design| / D_design) × 100% ``` Where: - `F` = Fidelity (%) - `D_actual` = Actual dimension - `D_design` = Designed dimension **Target**: F > 90% **Cell viability post-print**: - Minimum: 80% - Target: >90% --- ## 4. Bioreactor Systems ### 4.1 Bioreactor Types #### 4.1.1 Spinner Flask **Design**: - Magnetic stirrer - Suspended scaffolds - Volume: 50-500 mL **Advantages**: - Simple setup - Low cost - Dynamic culture **Parameters**: ``` Rotation speed: 40-100 rpm Medium volume: 100-250 mL Exchange rate: 50% daily Duration: 1-4 weeks ``` #### 4.1.2 Perfusion Bioreactor **Design**: - Continuous medium flow through scaffold - Peristaltic pump - Oxygen/nutrient control **Flow rate calculation**: ``` Q = v × A ``` Where: - `Q` = Flow rate (mL/min) - `v` = Flow velocity (mm/s) - `A` = Cross-sectional area (mm²) **Typical parameters**: ``` Flow rate: 0.1-5 mL/min Shear stress: 0.1-10 dyne/cm² Pressure: <10 kPa Medium exchange: Continuous ``` #### 4.1.3 Rotating Wall Vessel **Design**: - Horizontal rotation - Low shear environment - Simulated microgravity **Applications**: - Cartilage tissue - Hepatic tissue - Stem cell differentiation **Parameters**: ``` Rotation: 15-40 rpm Volume: 10-55 mL Culture time: 2-6 weeks ``` #### 4.1.4 Compression Bioreactor **Design**: - Cyclic mechanical loading - For load-bearing tissues **Loading parameters**: ``` Frequency: 0.1-1 Hz Strain: 5-15% Duration: 1-4 hours/day Rest period: 20-23 hours ``` **Applications**: Bone, cartilage, ligament, tendon ### 4.2 Culture Conditions #### 4.2.1 Temperature Control ``` T_optimal = 37°C ± 0.5°C ``` **Monitoring**: RTD sensors, ±0.1°C accuracy #### 4.2.2 pH Control ``` pH_optimal = 7.2-7.6 ``` **Control methods**: - CO₂ regulation (5-10%) - HEPES buffer (10-25 mM) - Automated pH monitoring #### 4.2.3 Oxygen Tension ``` pO₂ = 2-20% (tissue-dependent) ``` **Tissue-specific**: - Bone: 5-10% - Cartilage: 2-5% - Liver: 10-20% - Cardiac: 5-15% **Hypoxia benefits**: - Stem cell maintenance - Chondrogenesis - Angiogenesis stimulation #### 4.2.4 Nutrient Supply **Glucose consumption**: ``` r_glucose = k × C_cells ``` Where: - `r_glucose` = Consumption rate (mol/L/h) - `k` = Specific consumption rate - `C_cells` = Cell concentration **Medium composition**: - DMEM/F12 base - 10% FBS (or serum-free) - 1% penicillin/streptomycin - Growth factors (tissue-specific) ### 4.3 Monitoring and Control #### 4.3.1 Real-Time Sensors | Parameter | Sensor Type | Range | Accuracy | |-----------|-------------|-------|----------| | Temperature | RTD | 20-45°C | ±0.1°C | | pH | Glass electrode | 6-8 | ±0.05 | | Dissolved O₂ | Optical | 0-100% | ±2% | | Glucose | Enzymatic | 0-25 mM | ±0.5 mM | | Lactate | Enzymatic | 0-20 mM | ±0.5 mM | #### 4.3.2 Automated Feedback Control **PID controller**: ``` u(t) = K_p × e(t) + K_i × ∫e(t)dt + K_d × de(t)/dt ``` Where: - `u(t)` = Control signal - `e(t)` = Error (setpoint - measured) - `K_p, K_i, K_d` = PID gains --- ## 5. Vascularization Strategies ### 5.1 Importance of Vascularization **Oxygen diffusion limit**: ~100-200 μm **Rationale**: Tissues >2 mm thick require blood vessels for: - Oxygen delivery - Nutrient supply - Waste removal - Integration with host ### 5.2 Prevascularization Methods #### 5.2.1 Co-Culture with Endothelial Cells **Protocol**: 1. Seed parenchymal cells (day 0) 2. Add endothelial cells (day 3-7) - Ratio: 10:1 to 5:1 (parenchymal:endothelial) 3. Culture 7-14 days 4. Observe vessel formation (CD31 staining) **Growth factors**: - VEGF: 10-50 ng/mL - bFGF: 5-20 ng/mL - Ang-1: 50-100 ng/mL #### 5.2.2 Microfluidic Channels **Design**: ``` Channel diameter: 50-500 μm Spacing: 200-1000 μm Pattern: Branched network Flow rate: 0.01-1 mL/min ``` **Fabrication**: - Sacrificial material (gelatin, Pluronic F127) - Coaxial printing - Laser ablation **Endothelialization**: 1. Seed endothelial cells in channels 2. Rotate bioreactor (uniform coverage) 3. Flow medium after 24-48 hours 4. Mature 5-10 days #### 5.2.3 Growth Factor Delivery **Sustained release**: ``` M_t / M_∞ = 1 - exp(-kt) ``` Where: - `M_t` = Amount released at time t - `M_∞` = Total amount - `k` = Release rate constant **Delivery systems**: - Microspheres (PLGA) - Hydrogel encapsulation - Affinity binding (heparin) ### 5.3 In Vivo Vascularization #### 5.3.1 Arteriovenous Loop **Procedure**: 1. Create vascular loop (femoral artery-vein) 2. Embed in tissue construct 3. Implant subcutaneously 4. Allow 2-4 weeks for vessel ingrowth 5. Transfer to target site **Advantages**: - Rapid vascularization (7-14 days) - Mature vessels - Functional perfusion #### 5.3.2 Angiogenic Factor Induction **Host-mediated approach**: - Implant construct with VEGF - Host vessels infiltrate - Integration over 2-6 weeks **Factors**: - VEGF: 0.1-10 μg - bFGF: 0.5-5 μg - PDGF: 0.1-1 μg --- --- ## A.1 Bioprinting protocol Extrusion bioprinting protocol covers pre-print preparation (CAD slicing at 50-200 micrometre layer height; G-code generation; bioink mixing with cells), printer calibration (pressure 10-200 kPa; temperature 4-37 C; nozzle diameter 100-1000 micrometres; print speed 5-50 mm/s), and the print sequence (UV sterilise, prime nozzle, print first layer with extra adhesion, continue layer-by-layer with camera monitoring, post-print cross-link). Inkjet bioprinting (1-300 pL droplets, 1-10 kHz, 20-100 micrometre resolution, 3-12 mPa·s viscosity) and laser-assisted bioprinting (532-1064 nm wavelength, 10-100 ns pulse, 1-100 microJ/pulse, sub-10-micrometre resolution) follow analogous control-loop structures with method-specific calibration windows. ## A.2 Bioreactor operation protocol Spinner-flask culture: 40-100 rpm rotation, 100-250 mL medium, 50% daily exchange. Perfusion bioreactor: 0.1-5 mL/min flow rate, 0.1-10 dyne/cm^2 shear-stress envelope, less than 10 kPa transmural pressure, continuous medium exchange. Rotating-wall vessel: 15-40 rpm, simulated-microgravity culture for cartilage and hepatic constructs. Compression bioreactor: 0.1-1 Hz cyclic loading, 5-15% strain, 1-4 hours per day with 20-23 hour rest period. The protocol covers control-loop tuning (PID gain selection per setpoint), fault-tree analysis for cryogen/medium loss, and the alarm escalation matrix for class-A (qubit-research, clinical-grade) versus class-B (industrial) systems. ## A.3 Vascularization protocol Pre-vascularization via co-culture: seed parenchymal cells day 0, add endothelial cells day 3-7 at 5:1-10:1 ratio, culture 7-14 days under VEGF 10-50 ng/mL + bFGF 5-20 ng/mL + Ang-1 50-100 ng/mL, verify network formation with CD31 immunostaining. Microfluidic-channel vascularization uses sacrificial Pluronic F127 or gelatin templates with 50-500 micrometre channel diameter and 200-1000 micrometre spacing; channels are endothelialized post-print with 24-48 hour rotation seeding before flow start. In-vivo arteriovenous-loop pre-vascularization implants the construct around a femoral artery-vein loop for 2-4 weeks before transfer to the target site. ## A.4 Cross-linking and decellularization protocol UV photo-crosslinking: 365 nm or 405 nm at 5-50 mW/cm^2 for 5-15 minutes, with photoinitiator (LAP, Irgacure 2959) at 0.05-0.5% (w/v). Ionic cross-linking: Ca2+ at 100 mM for alginate, in 5-30 minute baths. Thermal cross-linking: 37 C for gelatin-methacryloyl and similar thermoresponsive systems. Decellularization protocol uses SDS or Triton X-100 detergent extraction with DNase/RNase digestion, with the residual-DNA target conventionally documented in the literature at less than 50 ng/mg dry tissue, and the post-decellularization GAG and collagen retention QC. ## A.5 Cell-seeding protocol Static seeding: pipette 10^6 cells/mL suspension onto the scaffold, incubate 2-4 hours for attachment, add culture medium, optionally flip the scaffold for uniform top/bottom seeding, expected efficiency 20-50%. Dynamic spinner seeding: 50 rpm for 4-8 hours, efficiency 40-70%. Vacuum seeding: 50-100 kPa vacuum for 5-10 minutes drives cells into pores, efficiency 60-90%. Centrifugal seeding: 100-500 ×g for 5-10 minutes, efficiency 70-95%. Each protocol carries a sterility envelope (laminar flow Class A; ISO 5 cleanroom for clinical-grade) and a chain-of-custody envelope so the QC team can trace any contamination back to the originating step. ## A.6 Replay and integrity defence Standard 96-bit nonce + 300-second skew window + 600-second seen-nonce cache for control-plane traffic. Bioreactor telemetry uses mTLS with per-channel monotonic counters; replay attempts are detected and dropped at the broker. Construct-lifecycle records are signed at each milestone, with the signature chain anchored into a Merkle tree per-batch so QC auditors can verify the construct provenance end-to-end. --- ## Z.1 Glossary, conformance, governance A companion glossary at `https://wiastandards.com/tissue-engineering/glossary/` expands every term used throughout this Phase. The conformance test suite at `https://github.com/WIA-Official/wia-tissue-engineering-conformance` walks every endpoint and protocol exchange. The reference container at `wia/tissue-engineering-host:1.0.0` ships every tissue-engineering envelope and endpoint with mock data so integrators can exercise the contract before wiring real backends. The companion CLI at `cli/tissue-engineering.sh` ships sample envelope generators with no dependencies beyond `jq` and POSIX shell. ## Z.2 Cross-standard composition (recap) This Phase composes with WIA-OMNI-API for credential storage, WIA-AIR-SHIELD for runtime trust list, WIA-SOCIAL Phase 3 §5 for federation handshake, WIA-INTENT for workload intent declaration, and (where personal data is processed) WIA Secure Enclave for sealed-data envelopes. The composition lets one host running multiple WIA family standards reuse one identity, one signing key chain, and one audit transport rather than maintaining N parallel implementations. ## Z.3 Implementation runbook A first implementation typically follows: stand up the reference container; run the conformance suite against it end-to-end; replace the mock backend with a real backend one endpoint at a time; wire audit-log replication out to the operations sink; onboard a single trusted peer for federation; expand to multiple peers; promote to production with the warning-envelope subscription enabled and the runbook in §Z.5 followed. ## Z.4 Backwards-compatibility promise Within the 1.x line, every Phase 1 envelope shape, every Phase 2 endpoint, and every Phase 3 protocol exchange MUST remain reachable and MUST continue to honour the documented status codes and content shapes. Hosts MAY add optional fields and new envelopes; hosts MUST NOT remove existing ones. Breaking changes ride a major version bump with a 12-month deprecation window per IETF RFC 8594 and 9745 and require a two-thirds Committee vote. ## Z.5 Closing implementer note This Phase fits inside the WIA Standards four-Phase architecture: Phase 1 envelopes are the wire-format contract; Phase 2 surfaces them through HTTPS; Phase 3 wraps them in protocol exchanges that cross trust boundaries; Phase 4 integrates with the broader ecosystem. Tissue-engineering deployments that follow this layering inherit the per-Phase conformance gates and the cross-standard composition behaviour described in Z.2. 弘益人間 — Benefit All Humanity.